DD231985A5 - Verfahren zur herstellung von pharmazeutischen zubereitungen mit depot-wirkung - Google Patents
Verfahren zur herstellung von pharmazeutischen zubereitungen mit depot-wirkung Download PDFInfo
- Publication number
- DD231985A5 DD231985A5 DD85273425A DD27342585A DD231985A5 DD 231985 A5 DD231985 A5 DD 231985A5 DD 85273425 A DD85273425 A DD 85273425A DD 27342585 A DD27342585 A DD 27342585A DD 231985 A5 DD231985 A5 DD 231985A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- granules
- tablets
- inert
- pharmaceutical preparations
- coating
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 6
- 230000000694 effects Effects 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 5
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000008187 granular material Substances 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims abstract description 8
- 230000035699 permeability Effects 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 12
- 229960000541 cetyl alcohol Drugs 0.000 description 9
- 239000000454 talc Substances 0.000 description 8
- 235000012222 talc Nutrition 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical class O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001012 codeine hydrochloride Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU84686A HU191246B (en) | 1984-02-21 | 1984-02-21 | Process for producing oral pharmaceutical compositions of retaed activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD231985A5 true DD231985A5 (de) | 1986-01-15 |
Family
ID=10950851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD85273425A DD231985A5 (de) | 1984-02-21 | 1985-02-20 | Verfahren zur herstellung von pharmazeutischen zubereitungen mit depot-wirkung |
Country Status (10)
| Country | Link |
|---|---|
| BG (1) | BG51340A3 (cs) |
| CS (1) | CS251786B2 (cs) |
| DD (1) | DD231985A5 (cs) |
| HU (1) | HU191246B (cs) |
| IT (1) | IT1185513B (cs) |
| PL (1) | PL145663B1 (cs) |
| RO (1) | RO93562B (cs) |
| SU (1) | SU1720474A3 (cs) |
| WO (1) | WO1985003636A1 (cs) |
| YU (1) | YU45233B (cs) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3707571A1 (de) * | 1986-03-11 | 1987-09-17 | Gentili Ist Spa | Verfahren zur herstellung von granulaten, das geeignet ist zur produktion von zur lang andauernden freisetzung beschichteten tabletten zur oralen verwendung |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE112163T1 (de) * | 1991-01-03 | 1994-10-15 | Glaxo Canada | Verfahren zur herstellung einer festem pharmazeutischen zusammensetzung. |
| HUT72408A (en) * | 1993-09-10 | 1996-04-29 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablets containing acetyl-salicylic acid |
| US6258381B1 (en) * | 2000-02-11 | 2001-07-10 | Mcneil-Ppc, Inc. | Tablet and process for making the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919436A (en) * | 1971-09-27 | 1975-11-11 | Eisai Co Ltd | Process for preparation of coated medicines |
| DE2347713C3 (de) * | 1972-09-25 | 1980-03-06 | Warner-Lambert Co., Morris Plains, N.J. (V.St.A.) | Acetylsalicylsäurekautablette |
| DE2446058A1 (de) * | 1974-09-26 | 1976-04-08 | Henning Berlin Gmbh | Galenische zubereitung fuer die allopurinol-dauertherapie |
| JPS5837285B2 (ja) * | 1975-05-29 | 1983-08-15 | カブシキガイシヤ ミドリジユウジ | チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ |
-
1984
- 1984-02-21 HU HU84686A patent/HU191246B/hu not_active IP Right Cessation
-
1985
- 1985-02-14 RO RO120458A patent/RO93562B/ro unknown
- 1985-02-14 WO PCT/HU1985/000008 patent/WO1985003636A1/de unknown
- 1985-02-20 DD DD85273425A patent/DD231985A5/de not_active IP Right Cessation
- 1985-02-21 YU YU266/85A patent/YU45233B/xx unknown
- 1985-02-21 PL PL1985252062A patent/PL145663B1/pl unknown
- 1985-02-21 IT IT8519584A patent/IT1185513B/it active
- 1985-02-21 CS CS851278A patent/CS251786B2/cs unknown
- 1985-10-17 SU SU853965111A patent/SU1720474A3/ru active
- 1985-10-21 BG BG072090A patent/BG51340A3/bg unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3707571A1 (de) * | 1986-03-11 | 1987-09-17 | Gentili Ist Spa | Verfahren zur herstellung von granulaten, das geeignet ist zur produktion von zur lang andauernden freisetzung beschichteten tabletten zur oralen verwendung |
Also Published As
| Publication number | Publication date |
|---|---|
| YU26685A (en) | 1988-02-29 |
| PL145663B1 (en) | 1988-10-31 |
| SU1720474A3 (ru) | 1992-03-15 |
| RO93562A (ro) | 1987-12-31 |
| CS251786B2 (en) | 1987-08-13 |
| PL252062A1 (en) | 1985-12-03 |
| WO1985003636A1 (en) | 1985-08-29 |
| CS127885A2 (en) | 1986-12-18 |
| BG51340A3 (bg) | 1993-04-15 |
| YU45233B (en) | 1992-05-28 |
| IT1185513B (it) | 1987-11-12 |
| RO93562B (ro) | 1988-01-02 |
| HUT37356A (en) | 1985-12-28 |
| IT8519584A0 (it) | 1985-02-21 |
| HU191246B (en) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68902954T2 (de) | Waessrige ueberzugsemulsion fuer pharmazeutische dosierungsformen. | |
| EP0181515B1 (de) | Verfahren zur Herstellung einer wässrigen Überzugsmitteldispersion und ihre Verwendung zum Überziehen von Arzneimitteln | |
| DE69802543T3 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
| DE69017915T2 (de) | Zubereitung für den magen. | |
| DE68917677T2 (de) | Vorrichtung für kontrollierte Wirkstoffabgabe mit einem undurchlässigen Ueberzug und Austrittsöffnung für die Wirkstoffabgabe. | |
| DE69000881T2 (de) | 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe. | |
| DE3586600T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| DE69620606T2 (de) | Feste oral anzuwendende arzeneiform | |
| DE69832108T2 (de) | Fenofibrathaltige Arzneizusammensetzung mit erhöhter Bioverfügbarkeit und Verfahren zu deren Herstellung | |
| DE69832816T2 (de) | Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung | |
| DE3872739T2 (de) | Arzneimittel mit langsamer freisetzung. | |
| AT391078B (de) | Verfahren zur herstellung von granulaten bzw. von presstabletten mit regulierter wirkstoffabgabe | |
| DE2741755C2 (de) | Überzugsmassen auf Polymerbasis für biologisch aktive Präparate, Verfahren zu ihrer Herstellung sowie mit diesen Überzugsmassen überzogene biologisch aktive Präparate und Verfahren zur Herstellung derselben | |
| DE1617724A1 (de) | Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkung | |
| EP0068191A2 (de) | Orale Dipyridamolformen | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE1093050B (de) | Verfahren zur Herstellung einer Penicillintablette mit verlaengerter Wirkung | |
| EP0355470A2 (de) | Retardierte Arzneiform und Verfahren zu ihrer Herstellung | |
| DE2732335C2 (de) | Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten | |
| DD231985A5 (de) | Verfahren zur herstellung von pharmazeutischen zubereitungen mit depot-wirkung | |
| DE69501183T2 (de) | Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung | |
| DE60032704T2 (de) | Filmtabletten mit minimierter Abhängigkeit von Nahrungsmitteleinfluss Anfälligkeit | |
| DE1944693C3 (de) | Pharmazeutische Zubereitung | |
| DE1944694C3 (de) | Pharmazeutische Zubereitung | |
| DE3942131C2 (de) | Pharmazeutisches Trimebutin-haltiges Präparat mit verlängerter Wirkstoff-Freisetzung und Verfahren zur Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |